Loading...
OTCM
SKVI
Market cap1mUSD
Dec 04, Last price  
0.35USD
1D
0.00%
1Q
52.24%
Jan 2017
2,087.50%
Name

Skinvisible Inc

Chart & Performance

D1W1MN
OTCM:SKVI chart
P/E
P/S
94.57
EPS
Div Yield, %
Shrs. gr., 5y
10.96%
Rev. gr., 5y
-14.26%
Revenues
20k
0.00%
850,280691,452777,685767,600287,269229,175180,185270,29866,69654,923174,635108,890629,02769,34743,166275,556663,426279,29620,00020,000
Net income
-566k
L-76.26%
-1,031,151-2,097,604-1,606,922-1,640,877-1,747,696-1,073,037-1,360,485-1,452,421-1,343,443-1,926,333-1,990,211-2,050,847-1,826,808158,342-2,722,287-2,641,559-2,285,796-2,211,342-2,382,440-565,654
CFO
-70k
L-9.49%
-204,501-862,075-743,872-947,355-350,50717,330-192,460-538,904-751,654-1,167,723-852,735-244,382-13,875-34,325-128,21245,765374,60545,170-77,157-69,834

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Skinvisible, Inc., together with its subsidiaries, focuses on the development, manufacture, and sale of topical, transdermal, and mucosal polymer-based delivery system technologies and formulations for use in pharmaceutical, over the counter, personal skincare, and cosmetic arenas. Its non-dermatological formulations offer solutions for women's health, pain management, and other markets. The company offers sunless tanning and sunscreen products under the Skinbrella name. It also licenses to pharmaceutical and consumer goods companies; assists pharmaceutical clients in the early development of the formulations; and provides solutions to pharmaceutical companies by reformulating their products coming off patent with a new Invisicare patent, and new product benefits and line extensions. The company was formerly known as Microbial Solutions, Inc. and changed its name to Skinvisible, Inc. in February 1999. Skinvisible, Inc. was incorporated in 1998 and is based in Las Vegas, Nevada.
IPO date
Jan 07, 1999
Employees
2
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT